Shopping Cart 0
Cart Subtotal
AED 0

Meiji Seika Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest , Depromel and others. It own and operates manufacturing and development technologies which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers its products for human and veterinary care. It operates research center, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.

Meiji Seika Pharma Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13

Partnerships 14

Meiji Seika Pharma Enters into Agreement with Santen Pharma 14

Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17

Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18

AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19

Licensing Agreements 20

Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20

Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22

Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23

Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24

Meiji Seika Pharma Enters into Licensing Agreement with MSD 25

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26

Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28

Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29

Acquisition 30

Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30

Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32

Meiji Seika Pharma Co Ltd-Key Competitors 33

Meiji Seika Pharma Co Ltd-Key Employees 34

Meiji Seika Pharma Co Ltd-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Joint Venture 36

Recent Developments 37

Corporate Communications 37

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson's disease in Japan and Asia 37

Product News 38

04/12/2018: Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology 38

Clinical Trials 39

Jun 05, 2018: Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018 39

Oct 20, 2017: Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meiji Seika Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13

Meiji Seika Pharma Enters into Agreement with Santen Pharma 14

Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17

Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18

AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19

Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20

Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22

Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23

Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24

Meiji Seika Pharma Enters into Licensing Agreement with MSD 25

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26

Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28

Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29

Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30

Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32

Meiji Seika Pharma Co Ltd, Key Competitors 33

Meiji Seika Pharma Co Ltd, Key Employees 34

Meiji Seika Pharma Co Ltd, Other Locations 35

Meiji Seika Pharma Co Ltd, Subsidiaries 35

Meiji Seika Pharma Co Ltd, Joint Venture 36

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Meiji Seika Pharma Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest , Depromel and others. It own and operates manufacturing and development technologies which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers its products for human and veterinary care. It operates research center, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.

Meiji Seika Pharma Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13

Partnerships 14

Meiji Seika Pharma Enters into Agreement with Santen Pharma 14

Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17

Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18

AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19

Licensing Agreements 20

Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20

Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22

Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23

Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24

Meiji Seika Pharma Enters into Licensing Agreement with MSD 25

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26

Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28

Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29

Acquisition 30

Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30

Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32

Meiji Seika Pharma Co Ltd-Key Competitors 33

Meiji Seika Pharma Co Ltd-Key Employees 34

Meiji Seika Pharma Co Ltd-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Joint Venture 36

Recent Developments 37

Corporate Communications 37

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson's disease in Japan and Asia 37

Product News 38

04/12/2018: Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology 38

Clinical Trials 39

Jun 05, 2018: Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018 39

Oct 20, 2017: Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meiji Seika Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13

Meiji Seika Pharma Enters into Agreement with Santen Pharma 14

Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17

Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18

AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19

Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20

Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22

Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23

Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24

Meiji Seika Pharma Enters into Licensing Agreement with MSD 25

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26

Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28

Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29

Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30

Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32

Meiji Seika Pharma Co Ltd, Key Competitors 33

Meiji Seika Pharma Co Ltd, Key Employees 34

Meiji Seika Pharma Co Ltd, Other Locations 35

Meiji Seika Pharma Co Ltd, Subsidiaries 35

Meiji Seika Pharma Co Ltd, Joint Venture 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Meiji Seika Pharma Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.